Literature DB >> 25145900

When do the risks of repeated courses of corticosteroids exceed the risks of surgery?

Randy M Leung1, Keith Dinnie, Timothy L Smith.   

Abstract

BACKGROUND: The management of chronic rhinosinusitis with nasal polyposis (CRSwNP) becomes unclear when patients require multiple courses of corticosteroids to maintain quality of life. Repeated courses of corticosteroids carry increased risks to patients. Although endoscopic sinus surgery (ESS) is an effective therapeutic modality, it also carries inherent risks. This study aims to identify the threshold at which the risks of repeated courses of corticosteroid exceed the risks of surgery.
METHODS: An evidence-based risk analysis was simulated using literature-reported complication rates, quality of life changes, and Medicare costs. Simulations were performed from the Medicare patient perspective, societal perspective, and the universal healthcare patient perspective.
RESULTS: All 3 simulations demonstrate a breakeven threshold favoring surgery over medical therapy when patients require oral corticosteroids (OCS) more often than once every 2 years in CRSwNP, once per year in CRSwNP/asthma, or twice per year for Samter's triad patients.
CONCLUSION: This represents the first rationalized evidence-based analysis for when surgery should be considered in place of repeated courses of oral corticosteroids. This threshold provides a guide for otolaryngologists to use when making clinical decisions with patients.
© 2014 ARS-AAOA, LLC.

Entities:  

Keywords:  Samter's triad; chronic sinusitis; corticosteroids; health economics; nasal polyps; risk analysis

Mesh:

Substances:

Year:  2014        PMID: 25145900     DOI: 10.1002/alr.21377

Source DB:  PubMed          Journal:  Int Forum Allergy Rhinol        ISSN: 2042-6976            Impact factor:   3.858


  10 in total

Review 1.  Surgical versus medical interventions in CRS and nasal polyps: comparative evidence between medical and surgical efficacy.

Authors:  Osama Dessouky; Claire Hopkins
Journal:  Curr Allergy Asthma Rep       Date:  2015-11       Impact factor: 4.806

Review 2.  Comprehensive review on endonasal endoscopic sinus surgery.

Authors:  Rainer K Weber; Werner Hosemann
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2015-12-22

Review 3.  Pharmacological Management of Chronic Rhinosinusitis: Current and Evolving Treatments.

Authors:  Daniel M Beswick; Stacey T Gray; Timothy L Smith
Journal:  Drugs       Date:  2017-10       Impact factor: 9.546

4.  THE 2017 13TH ANNUAL DAVID W. KENNEDY, MD, LECTURE The evolution of outcomes in sinus surgery for chronic rhinosinusitis: past, present, and future.

Authors:  Timothy L Smith
Journal:  Int Forum Allergy Rhinol       Date:  2017-10-13       Impact factor: 3.858

Review 5.  Burden of Disease in Chronic Rhinosinusitis with Nasal Polyps.

Authors:  Claus Bachert; Neil Bhattacharyya; Martin Desrosiers; Asif H Khan
Journal:  J Asthma Allergy       Date:  2021-02-11

6.  Herbal medicine for the treatment of chronic rhinosinusitis: A systematic review and meta-analysis.

Authors:  Boram Lee; Chan-Young Kwon; Man Young Park
Journal:  Front Pharmacol       Date:  2022-07-18       Impact factor: 5.988

7.  Cost-Utility Analysis of Dupilumab for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Italy.

Authors:  Eugenio De Corso; Gianluca Furneri; Daria Salsi; Francesca Fanelli; Gianluca Ronci; Giovanna Sala; Rossella Bitonti; Domenico Cuda
Journal:  J Pers Med       Date:  2022-06-10

Review 8.  Nasal polyps in patients with asthma: prevalence, impact, and management challenges.

Authors:  Cristobal Langdon; Joaquim Mullol
Journal:  J Asthma Allergy       Date:  2016-03-14

9.  Gelomyrtol for acute or chronic sinusitis: A protocol for systematic review and meta-analysis.

Authors:  Yongcan Wu; Xiaomin Wang; Demei Huang; Caixia Pei; Shuiqin Li; Zhenxing Wang
Journal:  Medicine (Baltimore)       Date:  2020-06-05       Impact factor: 1.817

10.  Management of chronic rhinosinusitis with steroid nasal irrigations: A viable nonsurgical alternative in the COVID-19 era.

Authors:  Auddie M Sweis; Tran B Locke; Jennifer E Douglas; Theodore C Lin; Brian M Sweis; Alyssa M Civantos; David W Kennedy
Journal:  Int Forum Allergy Rhinol       Date:  2020-07-16       Impact factor: 5.426

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.